Overachievers.

That's basically what follicular lymphoma cells are - B cells that forgot how to die. Your immune system normally runs a pretty tight ship when it comes to retiring old or broken cells, but follicular lymphoma cells carry a genetic cheat code (a translocation called t(14;18), if you want to impress someone at dinner) that cranks up a protein called BCL2. In other words, these cells have disabled their own self-destruct button. And because they're slow about it - growing at the pace of a lazy Sunday rather than a five-alarm fire - doctors call this cancer "indolent." Which, in medical-speak, basically means "annoying but patient."

For years, when follicular lymphoma came back after initial treatment (because it almost always does - it's like that friend who keeps showing up uninvited), oncologists reached for a combo called R² : rituximab plus lenalidomide. Rituximab is an antibody that tags cancer cells for destruction, while lenalidomide gives the immune system a kind of espresso shot, waking it up to do its job. Together, they've been a solid duo. Think of them as the buddy cop movie of lymphoma treatment.

Enter the Third Wheel (Who Actually Makes Things Better)

A new editorial by Dr. Loretta Nastoupil in Nature Reviews Clinical Oncology highlights something that doesn't happen often in cancer medicine: not one but two randomized phase 3 trials showing that adding a third drug to R² dramatically improves outcomes for patients with relapsed or refractory follicular lymphoma. Both are chemotherapy-free. Both work. And both just got FDA approval.

The EPCORE FL-1 Trial: Epcoritamab Joins the Party

First up: epcoritamab, a bispecific antibody. Basically, it's a molecular matchmaker - one arm grabs onto the cancer cell (via CD20), the other grabs a T cell (via CD3), and forces an introduction that ends very badly for the cancer cell. In other words, it physically drags your immune system's hired muscle right up to the tumor and says, "This one. Get this one."

The numbers from EPCORE FL-1 are hard to ignore. In 488 patients, the triplet of epcoritamab plus R² delivered an overall response rate of 95.1%, compared to 79.2% for R² alone. Complete response? 79.2% versus 49.8%. And progression-free survival at 16 months hit 85.5% in the triplet arm versus 40.2% in the control - a hazard ratio of 0.21 that made statisticians do a double-take (Falchi et al., The Lancet, 2025; DOI: 10.1016/S0140-6736(25)02360-8).

The kicker? It's entirely outpatient. No IV poles in hospital rooms. You get your shots and go home.

The inMIND Trial: Tafasitamab Takes a Different Route

Meanwhile, tafasitamab - an anti-CD19 antibody - took a slightly different approach. Instead of playing matchmaker, it targets CD19 on the B cell surface, giving the immune system a different handle to grab onto. The inMIND trial showed a 57% reduction in the risk of progression or death, with median progression-free survival stretching to 22.4 months versus 13.9 months for R² alone (Zinzani et al., The Lancet, 2025; DOI: 10.1016/S0140-6736(25)01787-8). And here's a nice bonus: the addition of tafasitamab didn't pile on significantly more toxicity.

So Which Triple Threat Do You Pick?

This is where it gets interesting - and where Dr. Nastoupil's editorial really earns its title. We've gone from one decent standard to two excellent options in the span of a year. The epcoritamab triplet brings jaw-dropping response rates but comes with cytokine release syndrome in about 35% of patients (manageable, but still something to watch). Tafasitamab's triplet is gentler on side effects but shows a more modest, though still meaningful, survival benefit.

In other words, oncologists now get to have the kind of problem they actually enjoy: choosing between two good options rather than making the best of one.

Why This Matters Beyond the Numbers

Follicular lymphoma affects roughly 15,000 new patients each year in the U.S. alone (Teras et al., CA Cancer J Clin, 2016; DOI: 10.3322/caac.21338). It's a disease that most people live with rather than die from - but that "living with" part involves repeated relapses, retreatments, and the constant low hum of uncertainty. Moving from a two-drug backbone to a three-drug regimen that keeps over 85% of patients progression-free at 16 months? That's not just a statistical improvement. That's more months of not thinking about cancer. More time between scans. More normal Tuesdays.

The R² era isn't ending so much as evolving. The horizon, as Dr. Nastoupil puts it, has expanded - and what's beyond it looks considerably better than what came before.

References:

1. Nastoupil LJ. Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma. Nat Rev Clin Oncol. 2026. DOI: 10.1038/s41571-026-01125-2. PMID: 41644727.

2. Falchi L, et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. The Lancet. 2025. DOI: 10.1016/S0140-6736(25)02360-8.

3. Zinzani PL, et al. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. The Lancet. 2025. DOI: 10.1016/S0140-6736(25)01787-8.

4. Leonard JP, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019;37(14):1188-1199. DOI: 10.1200/JCO.19.00010.

5. Teras LR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-459. DOI: 10.3322/caac.21338.

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.